Skip to main content

Table 1 Baseline clinical characteristics of study population

From: Poor predictability of QuantiFERON-TB assay in recipients and donors for tuberculosis development after kidney transplantation in an intermediate-TB-burden country

 

Recipients (n = 458)

Recipient-donor pairs (n = 239)

Recipients (n = 239)

Donors (n = 239)

Age, year (± SD)

44.5 ± 15.4

40.6 ± 16.1

45.9 ± 10.2

Male gender

300 (65.5)

157 (65.7)

103 (43.1)

History of TB infection

21 (4.6)

7 (2.9)

19 (7.9)

History of close contact with active TB

0 (0.0)

0 (0.0)

0 (0.0)

Abnormal chest radiography

17 (3.7)

7 (2.9)

14 (5.9)

 History of adequately treated TB

5 (1.1)

2 (0.8)

1 (0.4)

 History of untreated TB

12 (2.6)

5 (2.1)

13(5.4)

Underlying disease

 Hypertension

377 (82.3)

184 (77.0)

19 (7.9)

 Diabetes mellitus

110 (24.0)

49 (20.5)

1 (0.4)

 History of malignancy

32 (7.0)

9 (3.8)

0 (0.0)

 COPD

3(0.7)

1(0.4)

0 (0.0)

Laboratory findings

 WBC count (cells/μL)

6850.6 ± 3617.4

7004.2 ± 3633.4

6175.2 ± 1765.9

 Albumin (g/dL)

4.0 ± 1.6

3.9 ± 0.6

4.4 ± 0.4

Cholesterol (mg/dL)

160.4 ± 75.9

159.6 ± 97.9

197.9 ± 61.6

  1. COPD chronic obstructive pulmonary disease, SD standard deviation, TB tuberculosis, WBC white blood cells